Cancer · 2003 · 158 citations · 27 references
MedicineNuclear MedicineOncologyEndocrine OncologyMetastasisSurgical OncologyRadiation TherapyRadioiodine TherapyAutologous Stem Cell InfusionComplete Response AssessmentIodine-123 Metaiodobenzylguanidine ScintigraphyMedian Toxic DoseStem Cell Harvesting
BACKGROUND: 131I-Metaiodobenzylguanidine (131I-MIBG) can be used systemically to treat malignant pheochromocytoma. To improve outcome, the authors used higher levels of activity of 131I-MIBG than previously reported. The authors reported the response rates and toxicity levels in patients with malignant pheochromocytoma or paraganglioma who were treated with high-dose 131I-MIBG. METHODS: Following debulking surgery and stem cell harvest, 12 patients with malignant pheochromocytoma or paraganglioma were treated with 131I-MIBG. Five had received previous external beam radiation and/or chemotherapy. The median single treatment dose was 800 mCi (37 gigabecquerels; range, 386-866 mCi) or 11.5 mCi/kg (range, 5.6-18.3 mCi/kg). The median cumulative dose was 1015 mCi (range, 386-1690 mCi). RESULTS: Three patients had a complete response, two of whom had soft tissue and skeletal metastases. Their median follow-up was 45 months (range, 23-101 months). Seven patients had a partial response (PR), with a median follow-up 43 months (range, 6-47 months). Two patients without a response died with progressive disease (PD) and 2 patients with an initial PR died of PD at 13 and 11 months, respectively. Grade 3 thrombocytopenia occurred after 79% (15 of 19) of treatments had been administered. Grade 3 and 4 neutropenia followed 53% (10 of 19) and 19% (4 of 19) of treatments, respectively. One patient required stem cell infusion, and one developed primary ovarian failure. CONCLUSIONS: The single and cumulative doses of 131I-MIBG were approximately 2-3.5 times higher than those used at other centers. Unlike previous reports, two patients with both skeletal and soft tissue metastases had a complete response. Hematologic toxicity was significant but tolerable. High-dose 131I-MIBG may lead to long-term survival in patients with malignant pheochromocytoma.
27
Scintigraphic Localization of Pheochromocytoma
James C. Sisson, Marc Frager, Timothy W. Valk et al. · New England Journal of Medicine · 1981 · 546 citations
Current Management of Pheochromocytoma
William H. ReMine, GUAN C. CHONC, JOHN A. VAN HEERDEN et al. · Annals of Surgery · 1974 · 302 citations
Medicine, Endocrinology, Oncology +13
Pheochromocytoma in Italy: a multicentric retrospective study
Massimo Mannelli, L. Ianni, A. Cilotti et al. · European Journal of Endocrinology · 1999 · 225 citations
Medicine, Endocrinology, Oncology +17
Radiopharmaceutical treatment of malignant pheochromocytoma.
Sisson Jc, Brahm Shapiro, Beierwaltes Wh et al. · PubMed · 1984 · 224 citations